Complete listing of claims:

1. (previously presented) A compound of the formula



I

or a pharmaceutically acceptable salt thereof, wherein

A is N;

B is $-NR_1R_2$, $-CR_1R_2R_{11}$, $-C(=CR_2R_{12})R_1$, $-NHCHR_1R_2$, $-OCHR_1R_2$, $-SCHR_1R_2$, $-CHR_2OR_1$, $-CHR_1OR_2$, $-CHR_2SR_1$, $-C(S)R_2$, $-C(O)R_2$, $-CHR_2NR_1R_2$, $-CHR_1NHR_2$, $-CHR_1N(CH_3)R_2$, or $-NR_{12}NR_1R_2$;

Z is NH, O, S, $-N(C_1-C_2$ alkyl), $-NC(O)CF_3$, or $-C(R_{13}R_{14})$, wherein R_{13} and R_{14} are each, independently, hydrogen, trifluoromethyl or methyl, or one of R_{13} and R_{14} is cyano and the other is hydrogen or methyl, or $-C(R_{13}R_{14})$ is a cyclopropyl group, or Z is nitrogen or CH and forms a five or six membered heterocyclic ring fused with R_5, which ring optionally comprises two or three further hetero members selected independently from oxygen, nitrogen, NR_{12}, and $S(O)_m$, and optionally comprises from one to three double bonds, and is optionally substituted with halo, C_1-C_4 alkyl, $-O(C_1-C_4$ alkyl), NH_2, $NHCH_3$, $N(CH_3)_2$, CF_3, or OCF_3, with the proviso that said ring does not contain any –S-S-, -S-O-, -N-S-, or –O-O- bonds, and does not comprise more than two oxygen or $S(O)_m$ heterologous members;

R_1 is C(O)H, $C(O)(C_1-C_6$ hydrocarbyl), $C(O)(C_1-C_6$ hydrocarbylene)(C_3-C_8 cyclohydrocarbyl), $C(O)(C_3-C_8$ cyclohydrocarbylene)(C_3-C_8 cyclohydrocarbyl), $C(O)(C_1-C_6$ hydrocarbylene)(C_4-C_8 heterocyclohydrocarbyl), $-C(O)(C_3-C_8$ cyclohydrocarbylene)(C_4-C_8 heterocyclohydrocarbyl), C_1-C_6 hydrocarbyl, C_3-C_8 cyclohydrocarbyl, C_4-C_8 heterocyclohydrocarbyl, $-(C_1-C_6$ hydrocarbylene)(C_3-C_8 cyclohydrocarbyl), $-(C_3-C_8$ cyclohydrocarbylene)(C_3-C_8 cyclohydrocarbyl), $-(C_1-C_6$ hydrocarbylene)(C_4-C_8 heterocyclohydrocarbyl), $-(C_3-C_8$ cyclohydrocarbylene)(C_4-C_8 heterocyclohydrocarbyl), or –O-aryl, or $-O-(C_1-C_6$ hydrocarbylene)-aryl; wherein said aryl, C_4-C_8 heterocyclohydrocarbyl, C_1-C_6 hydrocarbyl, C_3-C_8 cyclohydrocarbyl, C_3-C_8 cyclohydrocarbylene, and C_1-C_6 hydrocarbylene groups may each independently be optionally substituted with from one to six fluoro and may each independently be optionally substituted with one or two substituents R_8 independently selected from the group consisting of C_1-C_4 hydrocarbyl, $-C_3-C_8$ cyclohydrocarbyl, hydroxy, chloro, bromo, iodo, CF_3, $-O-(C_1-C_6$ hydrocarbyl), $-O-(C_3-C_5$ cyclohydrocarbyl), $-O-CO-(C_1-$

C_4 hydrocarbyl), -O-CO-NH(C_1-C_4 hydrocarbyl), -O-CO-N(R_{24})(R_{25}), -N(R_{24})(R_{25}), -S(C_1-C_4 hydrocarbyl), -S(C_3-C_5 cyclohydrocarbyl), -N(C_1-C_4hydrocarbyl)CO(C_1-C_4 hydrocarbyl), -NHCO(C_1-C_4 hydrocarbyl), -COO(C_1-C_4 hydrocarbyl), -CONH(C_1-C_4 hydrocarbyl), -CON(C_1-C_4 hydrocarbyl)(C_1-C_2 hydrocarbyl), CN, NO_2, -OSO_2(C_1-C_4 hydrocarbyl), S^+(C_1-C_6 hydrocarbyl)(C_1-C_2 hydrocarbyl)I^-, -SO(C_1-C_4 hydrocarbyl) and -SO_2(C_1-C_4 hydrocarbyl); and wherein the C_1-C_6 hydrocarbyl, C_1-C_6 hydrocarbylene, C_5-C_8 cyclohydrocarbyl, C_5-C_8 cyclohydrocarbylene, and C_5-C_8 heterocyclohydrocarbyl moieties of R_1 may optionally independently contain from one to three double or triple bonds; and wherein the C_1-C_4 hydrocarbyl moieties and C_1-C_6 hydrocarbyl moieties of R_8 can optionally independently be substituted with hydroxy, amino, C_1-C_4 hydrocarbyl, aryl, -CH_2-aryl, C_3-C_5 cyclohydrocarbyl, or –O-(C_1-C_4 hydrocarbyl), and can optionally independently be substituted with from one to six fluoro, and can optionally contain one or two double or triple bonds; and wherein each heterocyclohydrocarbyl group of R_1 contains from one to three heteromoieties selected from oxygen, $S(O)_m$, nitrogen, and NR_{12};

R_2 is hydrogen, C_1-C_{12} hydrocarbyl, C_3-C_8 cyclohydrocarbyl, C_4-C_8 heterocyclohydrocarbyl, -(C_1-C_6 hydrocarbylene)(C_3-C_8 cyclohydrocarbyl), -(C_3-C_8 cyclohydrocarbylene)(C_3-C_8 cyclohydrocarbyl), -(C_1-C_6 hydrocarbylene)(C_4-C_8 heterocyclohydrocarbyl), -(C_3-C_8 cyclohydrocarbylene)(C_4-C_8 heterocyclohydrocarbyl), aryl, –(C_1-C_6 hydrocarbylene)aryl, or -(C_3-C_8 cyclohydrocarbylene)(aryl); wherein each of the foregoing R_2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, and C_1-C_6 hydrocarbyl, wherein one of said one to three substituents can further be selected from bromo, iodo, C_1-C_6 alkoxy, -OH, -O-CO-(C_1-C_6 hydrocarbyl), -O-CO-N(C_1-C_4 hydrocarbyl)(C_1-C_2 hydrocarbyl), -S(C_1-C_6 hydrocarbyl), -S(O)(C_1-C_6 hydrocarbyl), -$S(O)_2$(C_1-C_6 hydrocarbyl), S^+(C_1-C_6 hydrocarbyl)(C_1-C_2 hydrocarbyl)I^-, CN, and NO_2; and wherein the C_1-C_{12} hydrocarbyl, -(C_1-C_6 hydrocarbylene), and cyclohydrocarbyl groups of 5 - 8 carbon atoms, cyclohydrocarbylene groups of 5 to 8 carbon atoms and heterocyclohydrocarbyl groups of 5 to 8 atoms of R_2 may optionally independently contain from one to three double or triple bonds; and wherein each heterocyclohydrocarbyl group of R_2 contains from one to three heteromoieties selected from oxygen, $S(O)_m$, nitrogen, and NR_{12};

or when R_1 and R_2 are as in –NHCHR_1R_2, -OCHR_1R_2, -SCHR_1R_2, –CHR_1R_2 or -NR_1R_2, R_1 and R_2 of B may form a saturated 5- to 8-membered ring which may optionally contain one or two double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen, $S(O)_m$, nitrogen or NR_{12}; and which carbocyclic ring can optionally be substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, C_1-C_4 alkyl, fluoro, chloro, bromo, iodo, CF_3, -O-(C_1-C_4 alkyl), -O-CO-(C_1-C_4 alkyl), -O-CO-NH(C_1-C_4 alkyl), -O-CO-N(C_1-C_4 alkyl)(C_1-C_2 alkyl), -NH(C_1-C_4 alkyl), -N(C_1-C_2 alkyl)(C_1-C_4 alkyl), -S(C_1-C_4 alkyl), -N(C_1-C_4 alkyl)CO(C_1-C_4 alkyl), -NHCO(C_1-C_4 alkyl),-COO(C_1-C_4 alkyl), -CONH(C_1-C_4 alkyl), -CON(C_1-C_4 alkyl)(C_1-C_2 alkyl), CN,

NO_2, $-OSO_2(C_1-C_4$ alkyl), $-SO(C_1-C_4$ alkyl), and $-SO_2(C_1-C_4$ alkyl), wherein one of said one to three substituents can further be selected from phenyl;

R_3 is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF_3, NH_2, $NH(C_1-C_2$ alkyl), $N(CH_3)_2$, $-NHCOCF_3$, $-NHCH_2CF_3$, $S(O)_m(C_1-C_4$ alkyl), $CONH_2$, $-CONHCH_3$, $CON(CH_3)_2$, $-CF_3$, or CH_2OCH_3;

R_4 is hydrogen, C_1-C_4 hydrocarbyl, C_3-C_5 cycloalkyl, $-(C_1-C_4$ hydrocarbylene)$(C_3-C_5$ cycloalkyl), $-(C_3-C_5$ cycloalkylene)$(C_3-C_5$ cycloalkyl), cyano, fluoro, chloro, bromo, iodo, $-OR_{24}$, C_1-C_6 alkoxy, $-O-(C_3-C_5$ cycloalkyl), $-O-(C_1-C_4$ hydrocarbylene)$(C_3-C_5$ cycloalkyl), $-O-(C_3-C_5$ cycloalkylene)$(C_3-C_5$ cycloalkyl), $-CH_2SC(S)O(C_1-C_4$ hydrocarbyl), $-CH_2OF_3$, CF_3, amino, nitro, $-NR_{24}R_{25}$, $-(C_1-C_4$ hydrocarbylene)$-OR_{24}$, $-(C_1-C_4$ hydrocarbylene)Cl, $-(C_1-C_4$ hydrocarbylene)$NR_{24}R_{25}$, $-NHCOR_{24}$, $-NHCONR_{24}R_{25}$, $-C=NOR_{24}$, $-NHNR_{24}R_{25}$, $-S(O)_mR_{24}$, $-C(O)R_{24}$, $-OC(O)R_{24}$, -C(O)CN, $-C(O)NR_{24}R_{25}$, $-C(O)NHNR_{24}R_{25}$, and $-COOR_{24}$, wherein the hydrocarbyl and hydrocarbylene groups of R_4 may optionally independently contain one or two double or triple bonds and may optionally independently be substituted with one or two substituents R_{10} independently selected from hydroxy, amino, $-NHCOCH_3$, $-NHCOCH_2Cl$, $-NH(C_1-C_2$ alkyl), $-N(C_1-C_2$ alkyl)$(C_1-C_2$ alkyl), $-COO(C_1-C_4$ alkyl), -COOH, $-CO(C_1-C_4$ alkyl), C_1-C_6 alkoxy, C_1-C_3 thioalkyl, cyano and nitro, and with one to four substituents independently selected from fluoro and chloro;

R_5 is aryl or heteroaryl and is substituted with from one to four substituents R_{27} independently selected from halo, C_1-C_{10} alkyl, $-(C_1-C_4$ alkylene)$(C_3-C_8$ cycloalkyl), $-(C_1-C_4$ alkylene)$(C_4-C_8$ heterocycloalkyl), $-(C_3-C_8$ cycloalkyl), $-(C_4-C_8$ heterocycloalkyl), $-(C_3-C_8$ cycloalkylene)$(C_3-C_8$ cycloalkyl), $-(C_3-C_8$ cycloalkylene)$(C_4-C_8$ heterocycloalkyl), C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, nitro, cyano, $-NR_{24}R_{25}$, $-NR_{24}COR_{25}$, $-NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, $-CO(NOR_{22})R_{23}$, $-CO_2R_{26}$, $-C=N(OR_{22})R_{23}$, and $-S(O)_mR_{23}$; wherein said C_1-C_{10} alkyl, C_3-C_8 cycloalkyl, (C_1-C_4 alkylene), (C_3-C_8 cycloalkyl), (C_3-C_8 cycloalkylene), and (C_4-C_8 heterocycloalkyl) groups can be optionally substituted with from one to three substituents independently selected form C_1-C_4 alkyl, C_3-C_8 cycloalkyl, (C_1-C_4 alkylene)$(C_3-C_8$ cycloalkyl), $-(C_3-C_8$ cycloalkylene)$(C_3-C_8$ cycloalkyl), C_1-C_4 haloalkyl, hydroxy, C_1-C_6 alkoxy, nitro halo, cyano, $-NR_{24}R_{25}$, $-NR_{24}COR_{25}$, $NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, CO_2R_{26}, $-CO(NOR_{22})R_{25}$, and $-S(O)_mR_{23}$; and wherein two adjacent substituents of the R_5 group can optionally form a 5-7 membered ring, saturated or unsaturated, fused to R^5, which ring optionally can contain one, two, or three heterologous members independently selected from O, $S(O)_m$, and N, but not any –S-S-, -O-O-, -S-O-, or –N-S- bonds, and which ring is optionally substituted with C_1-C_4 alkyl, C_3-C_8 cycloalkyl, $-(C_1-C_4$ alkylene)$(C_3-C_8$ cycloalkyl), $-(C_3-C_8$ cyloalkylene)$(C_3-C_8$ cycloalkyl), C_1-C_4 haloalkyl, nitro, halo, cyano $-NR_{24}R_{25}$, $NR_{24}COR_{25}$, $NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, CO_2R_{26}, $-CO(NOR_{26})R_{25}$, or $-S(O)_mR_{23}$; wherein one of said one to four optional substituents R_{27} can further be selected from $-SO_2NH(C_1-C_4$ alkyl), $-SO_2NH(C_1-C_4$ alkylene)$(C_3-C_8$ cycloalkyl), $-SO_2NH(C_3-C_8$ cycloalkyl), $-SO_2NH(C_3-C_8$ cycloalkylene)$(C_3-C_8$ cycloalkyl), $-SO_2N(C_1-C_4$ alkyl)$(C_1-C_2$

alkyl), -SO_2NH_2, -$NHSO_2$(C_1-C_4 alkyl), -$NHSO_2$(C_3-C_8 cycloalkyl), -$NHSO_2$(C_1-C_4 alkylene)(C_3-C_8 cycloalkyl), and -$NHSO_2$(C_3-C_8 cycloalkylene)(C_3-C_8 cycloalkyl); and wherein the alkyl, and alkylene groups of R_5 may independently optionally contain one double or triple bond;

R_{11} is hydrogen, hydroxy, fluoro, ethoxy, or methoxy;

R_{12} is hydrogen or C_1-C_4 alkyl;

R_{22} is independently at each occurrence selected from hydrogen, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_3-C_6 alkenyl, C_3-C_6 alkynyl, C_3-C_8 cycloalkyl, (C_3-C_8 cycloalkylene)(C_3-C_8 cycloalkyl), and (C_1-C_4 alkylene)(C_3-C_8 cycloalkyl);

R_{23} is independently at each occurrence selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_2-C_8 alkoxyalkyl, C_3-C_8 cycloalkyl, -(C_1-C_4 alkylene)(C_3-C_8 cycloalkyl), -(C_3-C_8 cycloalkylene)(C_3-C_8 cycloalkyl), aryl, -(C_1-C_4 alkylene)aryl, piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, and thiomorpholine;

R_{24} and R_{25} are independently at each occurrence selected from hydrogen, -C_1-C_4 alkyl, C_1-C_4 haloalkyl, especially CF_3, -CHF_2, CF_2CF_3, or CH_2CF_3, -(C_1-C_4 alkylene)OH, -(C_1-C_4 alkylene)-O-(C_1-C_4 alkyl), -(C_1-C_4 alkylene)-O-(C_3-C_5 cycloalkyl), C_3-C_8 cycloalkyl, -(C_1-C_4 alkylene)(C_3-C_8 cycloalkyl), -(C_3-C_8 cycloalkylene)(C_3-C_8 cycloalkyl), -C_4-C_8 heterocyclohydrocarbyl, -(C_1-C_4 alkylene)(C_4-C_8 heterocyclohydrocarbyl), -(C_3-C_8 cycloalkylene)(C_4-C_8 heterocyclohydrocarbyl), aryl, and -(C_1-C_4 alkylene)(aryl), wherein the -C_4-C_8 heterocyclohydrocarbyl groups can each independently optionally be substituted with aryl, CH_2-aryl, or C_1-C_4 alkyl, and can optionally contain one or two double or triple bonds; or, when R_{24} and R_{25} are as $NR_{24}R_{25}$, -$C(O)NR_{24}R_{25}$, -(C_1-C_4 alkylene)$NR_{24}R_{25}$, or -$NHCONR_{24}R_{25}$, then $NR_{24}R_{25}$ may further optionally form a 4 to 8 membered heterocyclic ring optionally containing one or two further hetero members independently selected from $S(O)_m$, oxygen, nitrogen, and NR_{12}, and optionally containing from one to three double bonds;

R_{26} is independently at each occurrence selected from C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_3-C_8 cycloalkyl, -(C_1-C_4 alkylene)(C_3-C_8 cycloalkyl), -(C_3-C_8 cycloalkylene)(C_3-C_8 cycloalkyl), aryl, and -(C_1-C_4 alkylene)(aryl); and

wherein each m is independently zero, one, or two,

with the proviso that heterocycloalkyl groups of the compound of formula I, II, or III do not comprise any –S-S-, -S-O-, -N-S-, or –O-O- bonds, and do not comprise more than two oxygen or $S(O)_m$ heterologous members.

2. (previously presented) A compound according to claim 1 of the formula



I , wherein

A is N;

B

is $-NR_1R_2$, $-CR_1R_2R_{11}$, $-C(=CR_2R_{12})R_1$, $-NHCHR_1R_2$, $-OCHR_1R_2$, $-SCHR_1R_2$, $-CHR_2OR_{12}$, $-CHR_2SR_{12}$, $-C(S)R_2$ or $-C(O)R_2$;

Z is NH, O, S, $-N(C_1-C_2$ alkyl) or $-C(R_{13}R_{14})$, wherein R_{13} and R_{14} are each, independently, hydrogen, trifluoromethyl or methyl, or one of R_{13} and R_{14} is cyano and the other is hydrogen or methyl;

R_1 is C_1-C_6 hydrocarbyl which may optionally be substituted with one or two substituents R_8 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3, C_1-C_4 alkoxy, $-O-CO-(C_1-C_4$ hydrocarbyl), $-O-CO-NH(C_1-C_4$ hydrocarbyl), $-O-CO-N(C_1-C_4$ hydrocarbyl)(C_1-C_2 hydrocarbyl), $-NH(C_1-C_4$ hydrocarbyl), $-N(C_1-C_2$ hydrocarbyl)(C_1-C_4 hydrocarbyl), $-S(C_1-C_4$ hydrocarbyl), $-N(C_1-C_4$hydrocarbyl)$CO(C_1-C_4$ hydrocarbyl), $-NHCO(C_1-C_4$ hydrocarbyl), $-COO(C_1-C_4$ hydrocarbyl), $-CONH(C_1-C_4$ hydrocarbyl), $-CON(C_1-C_4$ hydrocarbyl)(C_1-C_2 alkyl), CN, NO_2, $-SO(C_1-C_4$ hydrocarbyl) and $-SO_2(C_1-C_4$ hydrocarbyl), and wherein said C_1-C_6 hydrocarbyl and the (C_1-C_4)hydrocarbyl moieties in the foregoing R_1 groups may optionally contain one carbon-carbon double or triple bond;

R_2 is C_1-C_{12} hydrocarbyl, aryl or $-(C_1-C_4$ hydrocarbylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or $-(C_1-C_6$ alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said $-(C_1-C_6$ alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by $N-R_9$ wherein R_9 is hydrogen or C_1-C_4 alkyl; and wherein each of the foregoing R_2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C_1-C_4 alkyl, or with one substituent selected from bromo, iodo, C_1-C_6 alkoxy, $-O-CO-(C_1-C_6$ alkyl), $-O-CO-N(C_1-C_4$ alkyl)(C_1-C_2 alkyl), $-S(C_1-C_6$ alkyl), CN, NO_2, $-SO(C_1-C_4$ alkyl), and $-SO_2(C_1-C_4$ alkyl), and wherein said C_1-C_{12} hydrocarbyl and the C_1-C_4 hydrocarbylene moiety of said $-(C_1-C_4$ hydrocarbylene)aryl may optionally contain one carbon-carbon double or triple bond;

or $-NR_1R_2$ or $-CR_1R_2R_{11}$ may form a saturated 5- to 8-membered carbocyclic ring which may optionally contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom;

R_3 is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF_3, methylthio, methylsulfonyl, CH_2OH, or CH_2OCH_3;

R_4 is hydrogen, C_1-C_4 hydrocarbyl, fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethoxy, $-CH_2OCH_3$, $-CH_2OCH_2CH_3$, $-CH_2CH_2OCH_3$, $-CH_2OF_3$, CF_3, amino, nitro, $-NH(C_1$-C_4 alkyl), $-N(CH_3)_2$, $-NHCOCH_3$, $-NHCONHCH_3$, $-SO_n(C_1$-C_4 alkyl) wherein n is 0, 1 or 2, cyano, hydroxy, $-CO(C_1$-C_4 alkyl), -CHO, cyano or $-COO(C_1$-C_4 alkyl) wherein said C_1-C_4 hydrocarbyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, $-NHCOCH_3$, $-NH(C_1$-C_2 alkyl), $-N(C_1$-C_2 alkyl)$_2$, $-COO(C_1$-C_4 alkyl), $-CO(C_1$-C_4 alkyl), C_1-C_3 alkoxy, C_1-C_3 thioalkyl, fluoro, chloro, cyano and nitro;

R_5 is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each of the above groups R_5 is substituted with from one to three substituents independently selected from fluoro, chloro, C_1-C_6 alkyl, and C_1-C_6 alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, $-(C_1$-C_6 alkyl)$O(C_1$-C_6)alkyl, $-NHCH_3$, $-N(CH_3)_2$, -COOH, $-COO(C_1$-C_4 alkyl), $-CO(C_1$-C_4 alkyl), $-SO_2NH(C_1$-C_4 alkyl), $-SO_2N(C_1$-C_4 alkyl)$(C_1$-C_2 alkyl), $-SO_2NH_2$, $-NHSO_2(C_1$-C_4 alkyl), $-S(C_1$-C_6 alkyl) and $-SO_2(C_1$-C_6 alkyl), and wherein the C_1-C_4 alkyl and C_1-C_6 alkyl moieties of the foregoing R_5 groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

R_{11} is hydrogen, hydroxy, fluoro, or methoxy;

R_{12} is hydrogen or C_1-C_4 alkyl; and

or a pharmaceutically acceptable salt of such compound.

3. (previously presented) A compound according to claim 2 wherein B is $-NR_1R_2$, $-NHCHR_1R_2$, $-SCHR_1R_2$ or $-OCHR_1R_2$; R_1 is C_1-C_6 hydrocarbyl, which may optionally be substituted with one hydroxy, fluoro, CF_3, or C_1-C_2 alkoxy group and may optionally contain one double or triple bond; and R_2 is benzyl or C_1-C_6 alkyl which may optionally contain one carbon-carbon double or triple bond, wherein said C_1-C_6 alkyl or the phenyl moiety of said benzyl may optionally be substituted with fluoro, CF_3, C_1-C_2 alkyl, or C_1-C_2 alkoxy.

4. (previously presented) A compound according to claim 2 wherein R_1 is C_1-C_6 hydrocarbyl which may be substituted by fluoro, CF_3, hydroxy, C_1-C_2 alkyl or C_1-C_2 alkoxy and which may optionally contain one carbon-carbon double or triple bond.

5. (previously presented) A compound according to claim 2 wherein R_2 is C_1-C_4 alkyl which may optionally be substituted by fluoro, chloro, CF_3, C_1-C_4 alkyl or C_1-C_4 alkoxy.

6. (previously presented) A compound according to claim 2 wherein R_3 is methyl, chloro, or methoxy.

7. (previously presented) A compound according to claim 2 wherein R_4 is methyl, -CH_2OH, cyano, trifluoromethoxy, methoxy, chloro, trifluoromethyl, -$COOCH_3$, -CH_2OCH_3, -CH_2Cl, -CH_2F, ethyl, amino or nitro.

8. (previously presented) A compound according to claim 2 wherein R_5 is phenyl substituted with two or three substituents.

9. (previously presented) A compound according to claim 2 wherein R_5 is pyridyl substituted with two or three substituents.

10. (previously presented) A compound according to claim 8 wherein said substitutents are selected, independently, from fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethyl, C_1-C_6 alkyl which may optionally be substituted with one hydroxy, C_1-C_4 alkoxy or fluoro group and which may optionally contain one carbon-carbon double or triple bond, -(C_1-C_4 alkylene)O(C_1-C_2 alkyl), C_1-C_3 hydroxyalkyl, hydroxy, formyl, COO(C_1-C_2 alkyl), -(C_1-C_2 alkylene)amino, and -(C(O)(C_1-C_4 alkyl).

11. (previously presented) A compound according to claim 9 wherein said substitutents are selected, independently, from fluoro, chloro, bromo, iodo, C_1-C_4 alkoxy, trifluoromethyl, C_1-C_6 alkyl which may optionally be substituted with one hydroxy, C_1-C_4 alkoxy or fluoro group and which may optionally contain one carbon-carbon double or triple bond, -(C_1-C_4 alkylene)O(C_1-C_2 alkyl), C_1-C_3 hydroxyalkyl, hydroxy, formyl, -COO(C_1-C_2 alkyl), -(C_1-C_2 alkylene)amino, and -(C(O)(C_1-C_4 alkyl).

12. (previously presented) A compound according to claim 1, wherein said compound is

4-(1-ethyl-propoxy)-2,5-dimethyl-6-(2,4,6-trimethyl-benzyl)-pyrimidine;

[2,5-dimethyl-6-(2,4,6-trimethyl-phenoxy)-pyrimidin-4-yl](1-ethyl-propyl)-amine;

(1-ethyl-propyl)-[2-methyl-5-nitro-6-(2,4,6-trimethyl-pyridin-3-yloxy)-pyrimidin-4-yl]-amine;

(N-(1-ethyl-propyl)-2-methyl-5-nitro-N□-(2,4,6-trimethyl-pyridin-3-yl)-pyrimidine-4,6-diamine;

4-(1-ethylpropoxy)-2,5-dimethyl-6-(2,4,6-trimethylphenoxy)-pyrimidine;

N-butyl-N-ethyl-2,5-dimethyl-N'-(2,4,6-trimethylphenyl)-pyrimidine-4,6-diamine; or

6-(1-ethyl-propoxy)-2-methyl-N4-(2,4,6-trimethyl-phenyl)-pyrimidine-4,5-diamine;

or a pharmaceutically acceptable salt of one of the above compounds.

13-28. (cancelled)

29 (previously presented). A compound as claimed in claim 1 wherein R_{24} and R_{25} are selected from -CF_3, -CHF_2, CF_2CF_3, and CH_2CF_3.

30 (cancelled)

31 (currently amended) A pharmaceutical composition ~~as claimed in claim 13~~ for treatment of an inflammatory disorder selected from the group consisting of rheumatoid arthritis and osteoarthritis in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of such disorder, and a pharmaceutically acceptable carrier.

32 (currently amended). A pharmaceutical composition ~~as claimed in claim 14~~ for treatment of depression, selected from the group consisting of major depression, single episode depression, recurrent depression, and child abuse induced depression in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of depression, and a pharmaceutically acceptable carrier.

33 (currently amended) A pharmaceutical composition ~~as claimed in claim 14~~ for treatment of neurodegenerative diseases selected from the group consisting of Alzheimer's disease, Parkinson's disease and Huntington's disease in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of such neurodegenerative diseases, and a pharmaceutically acceptable carrier.

34 (currently amended) A pharmaceutical composition ~~as claimed in claim14~~ for treatment of chemical dependencies or addictions, selected from the group consisting of dependencies or addictions to alcohol, cocaine, heroin, benzodiazapines, or other drugs in a mammal, comprising an amount of a compound according to 1 that is effective in the treatment of such chemical dependencies or addictions, and a pharmaceutically acceptable carrier.

35 (currently amended) A pharmaceutical composition ~~as claimed in claim 14~~ for treatment of cerebral ischemia in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of cerebral ischemia, and a pharmaceutically acceptable carrier.

36 (currently amended). A pharmaceutical composition ~~as claimed in claim 14~~ for treatment of immune dysfunctions induced by stress selected from the group consisting of porcine stress syndrome, bovine shipping fever, equine paroxysmal fibrillation, confinement dysfunction in chicken, sheering stress in sheep, and human animal interaction stress in dogs, comprising an amount of a compound according to claim 1 that is effective in the treatment of such immune dysfunctions, and a pharmaceutically acceptable carrier.

37 (currently amended) A pharmaceutical composition ~~as claimed in claim 14~~ for treatment of fibromyalgia in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of fibromyalgia, and a pharmaceutically acceptable carrier.

38 (currently amended) A pharmaceutical composition ~~as claimed in claim 14~~ for treatment of anorexia or bulimia nervosa in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of anorexia or bulimia nervosa, and a pharmaceutically acceptable carrier.

39 (currently amended). A pharmaceutical composition ~~as claimed claim 14~~ for treatment of cerebral ischemia, selected from the group consisting of

cerebral hippocampal ischemia in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of cerebral hippocampal ischemia, and a pharmaceutically acceptable carrier.

40 (currently amended). A pharmaceutical composition ~~as claimed in claim 14~~ for treatment of social phobia, agoraphobia, or specific phobias in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of such phobias, and a pharmaceutically acceptable carrier.

41 (currently amended). ~~The~~ A pharmaceutical composition ~~according to claim 13 wherein the pain perception is~~ for treatment of fibromyalgia in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of fibromyalgia, and a pharmaceutically acceptable carrier.

42 (currently amended). ~~The~~ A pharmaceutical composition ~~according claim 13 wherein the ischemic neuronal damage is~~ for treatment of cerebral ischemia in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of cerebral ischemia, and a pharmaceutically acceptable carrier.

43 (currently amended). ~~The~~ A pharmaceutical composition ~~according to claim 14~~ for the treatment of depression or postpartum depression in a mammal, comprising an amount of a compound according to claim 1 that is effective in the treatment of such depression, and a pharmaceutically acceptable carrier.

44-45 (cancelled).

46. (previously presented) The compound of claim 1, wherein Z is NH, O, S, $NC(OC)CF_3$, or $CR_{13}R_{14}$.

47. (previously presented) The compound of claim 46, wherein Z is NH, S, $NC(OC)CF_3$, or $CR_{13}R_{14}$.

48. (previously presented) The compound of claim 46, wherein Z is NH.

REMARKS

This is in response to the Official Action of April 20, 2005 for the above-captioned application. Claims 1-12, 29 and 31-48 are allowed.

To expedite prosecution, Applicants hereby cancel Claims 13, 14 and 30, without prejudice to the filing of claims directed to the subject matter of Claims 13, 14 and/or 30 in separate applications. Claims 31-43 have been amended to change the claim dependencies and to recite in each case that the composition is a composition comprising an amount of a compound according to claim 1 that is effective in the treatment of the condition recited in each case. Claims 44-45 have been cancelled.

In view of the foregoing, allowance of all pending claims in the application is respectfully requested.

Please charge any appropriate fee to cover this submission to Pfizer Deposit Account No. 16-1445. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: June 23, 2005

Andrea E. Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer, Inc.
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212) 733-1898